Coherus Oncology, Inc. — Form 8-K

Coherus Oncology announced a special dividend of contingent value rights (CVRs) to stockholders on a 1:1 basis with common stock, with a Record Date of September 30, 2026 and Distribution Date of October 7, 2026. CVR holders will receive pro rata shares of net cash proceeds from the sale or monetization of Legacy BioSim Assets (patents, royalties, cell lines, materials) during a two-year term ending October 7, 2028. The company has retained an investment bank to execute a sale process, but CVR payments are contingent on dispositions occurring and net of taxes, transaction expenses, and permitted deductions; no minimum payment is guaranteed. A new Loan Agreement with Innovatus Life Sciences dated August 12, 2026 contains restrictions on asset dispositions and CVR payments.